Conceptus(R) Announces Enrollment of First Patient in European Clinical Trial for Next Generation Essure(R)

Conceptus(R) Announces Enrollment of First Patient in European Clinical Trial
for Next Generation Essure(R)

MOUNTAIN VIEW, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Conceptus, Inc.
(Nasdaq:CPTS), developer of the Essure^® procedure, the leading surgery-free
permanent birth control method, announced today that it has initiated
enrollment in its European clinical study designed to support the company's CE
Mark application for its next generation Essure device.

The European clinical trial will enroll up to 60 patients in multiple sites in
Europe, and will assess effectiveness for pregnancy prevention at both the
3-months and 1-year endpoints. Dr. Sebastiaan Veersema, the trial's principal
investigator, at St. Antonius Hospital in Nieuwegein, Netherlands, performed
the first procedure in the clinical study on January 31, 2013.

The key benefit of the next generation Essure design is immediate, permanent
contraception without a three-month waiting period or 90-day confirmation
test. To achieve immediate contraception, a proprietary hydrogel component is
incorporated into the distal end of what is otherwise very similar to the
current Essure insert, and which is intended to immediately occlude the
fallopian tube once the device is placed.

"We are pleased to participate in the world's first clinical trial evaluating
safety and effectiveness of the next generation Essure that can be immediately
relied upon for contraception. This product could revolutionize female
permanent birth control. We are highly encouraged by the successful placement
of the first patient enrolled with Conceptus' innovative contraceptive
technology," stated Dr. Veersema.

"We are enthusiastic to have initiated enrollment in Europe with our next
generation Essure device ahead of our timing expectations. With immediate
confirmation and very little additional training requirements, we believe this
groundbreaking technology will dramatically strengthen our competitive
positioning against surgical tubal ligation," said D. Keith Grossman,
President and Chief Executive Officer of Conceptus.

About the Essure^® Procedure

The Essure procedure, FDA approved since 2002, is the only surgery-free and
hormone-free permanent birth control method that can be performed in the
comfort of a physician's office in less than 10 minutes (average hysteroscopic
time) without the risks associated with general anesthesia or tubal ligation.
Soft, flexible inserts are placed in a woman's fallopian tubes through the
cervix without incisions. Over the next three months, the body forms a natural
barrier around and through the inserts to prevent sperm from reaching the
egg.Three months after the Essure procedure, an Essure Confirmation Test is
given to confirm that the inserts are in place and that the fallopian tubes
are blocked, verifying that the patient can rely on Essure for permanent birth

The Essure procedure is 99.83% effective based on five years of follow up with
zero pregnancies reported in clinical trials, making it the most effective
permanent birth control available.Essure's 10-year commercial data tracks
closely with its five-year clinical results, and Essure has been proven and
trusted by physicians since 2002.The Essure procedure is covered in the U.S.
by most public and private insurance plans and approximately 730,000 women
worldwide have undergone the procedure.

About Conceptus^®, Inc.

Conceptus, Inc. is the leader in the development of innovative device-based
solutions in permanent birth control. The Company manufactures and markets the
Essure procedure.The Essure procedure is available in the United States,
Europe, Australia, New Zealand, Canada, Mexico, Central and South America and
the Middle East.

Please visit for more information on the Essure procedure.
Patients may call the Essure Information Center at 1-877-ESSURE-1 with
questions or to find a physician in their area.

The Conceptus, Inc. logo is available at

Forward Looking Statements

This press release includes forward-looking statements, the accuracy of which
is subject to known and unknown risks and uncertainties.These forward-looking
statements include, without limitation, discussions regarding the company's
ability to successfully complete enrollment or to achieve successful results
including the ability to achieve immediate occlusion in the European clinical
study of its second generation product and its ability to compete effectively
against tubal ligations.These discussions and other forward-looking
statements included herein may differ significantly from actual results. Such
differences may be based upon factors such as changes in strategic planning
decisions by management, re-allocation of internal resources, changes in the
impact of domestic and global macroeconomic pressures, reimbursement decisions
by insurance companies and domestic and foreign governments, scientific
advances by third parties, risks of international operations, litigation
risks, and attempts to amend or repeal all or part of the Patient Protection
and Affordable Care Act of 2010 as amended, as well as those factors set forth
in the company's most recent Annual Report on Form 10-K and most recent
Quarterly Report on Form 10-Q, and other filings with the Securities and
Exchange Commission.These forward-looking statements speak only as to the
date on which the statements were made.The company undertakes no obligation
to update or revise publicly any forward-looking statements, whether as a
result of new information, future events, or otherwise.

2013 Conceptus, Inc. – All rights reserved. Conceptus and Essure are
trademarks or registered trademarks of Conceptus, Inc.

CONTACT: Investor and Public Relations Contact:
         Lynn Pieper
         Westwicke Partners
         (415) 202-5678

Conceptus, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.